Status:

TERMINATED

Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

Lead Sponsor:

Veloxis Pharmaceuticals

Conditions:

Chemotherapy-induced Peripheral Neuropathy

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

To evaluate the safety and tolerability of ART-123 in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab

Detailed Description

To compare the safety and tolerability of ART-123 to placebo in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab

Eligibility Criteria

Inclusion

  • 18 years of age or older
  • Metastatic colorectal cancer; pathologically confirmed adenocarcinoma of the colon or rectum
  • ECOG performance status of 0 or 1
  • The most recent laboratory findings (including for liver and kidney) within 14 days prior to randomization remain within acceptable ranges Willingness of the patient and the sexual partner to use a highly effective contraceptive method during the course of the study
  • Able to sufficiently understand the clinical study and give written informed consent

Exclusion

  • History of major hemorrhage
  • High risk of hemorrhage
  • History of other malignancies
  • Active ulcer
  • Patients using anti-coagulants and fibrinolytic drugs
  • Active Hepatitis B, or known HBs antigen positive
  • Prior treatment history with thrombomodulin alfa
  • Administration of another investigational medicinal product within 30 days prior to randomization
  • Patient is pregnant (positive urine human chorionic gonadotropin) or breastfeeding or intends to get pregnant during the Treatment period
  • Patients otherwise deemed as inappropriate to participate in the study by the Investigator

Key Trial Info

Start Date :

March 24 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 5 2024

Estimated Enrollment :

77 Patients enrolled

Trial Details

Trial ID

NCT05251727

Start Date

March 24 2022

End Date

June 5 2024

Last Update

August 19 2024

Active Locations (32)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (32 locations)

1

Beverly Hills Cancer Center

Beverly Hills, California, United States, 90210

2

UCLA Dept. of Medicine - Hematology/Oncology

Los Angeles, California, United States, 90095

3

Eastern Connecticut Hematology & Oncology Associates

Norwich, Connecticut, United States, 06360

4

Mid-Florida Hematology & Oncology Centers

Orange City, Florida, United States, 32763

Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients | DecenTrialz